- Lipoprotein(a) Reduction in Persons with Cardiovascular DiseaseNew England Journal of Medicine, 2020, 382(21): e65.被引 1
- Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemiaPeng, Yanren; Guo, Danxia; Jiang, Sijie; Zheng, Hua*Chinese Medical Journal, 2022, 135(6): 730-731.
- A systematic review and meta-analysis of randomized controlled trials on the impact of ezetimibe on carotid intima-media thicknessKwon, Ryuk Jun; Son, Soo Min26th World Congress of Neurology (WCN), Montreal, CANADA, 2023-10-15 To 2023-10-19.
期刊论文
Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis
16阅读
